




**Pancreatic  
Adenocarcinoma**

## Work Up




\* Note:


If tissue proved, optional testing for BRCA ½、MMR、NTRK

## 《 PANC-2 》

### Work Up




- RESECTABLE
- BORDERLINE RESECTABLE NO METASTASES, PLANNED NEOADJUVANT THERAPY
- BORDERLINE RESECTABLE NO METASTASES, PLANNED RESECTION.




## 《 PANC-6 》

### POST-OP ADJUVANT TREATMENT




LOCALLY ADVANCED UNRESECTABLE



## 《 PANC-8 》


### METASTATIC DISEASE



\* Note:

If tissue proved, optional testing for BRCA ½、MMR、NTRK

RECURRENCE AFTER RESECTION





## 《References》

1. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma Version 3.2024.
2. Mornex F, Girard N, Delpero J-R, Partensky C. Radiochemotherapy in the management of pancreatic cancer –part I: neoadjuvant treatment. *Semin Radiat Oncol* 2005;15:226-234
3. Bickenbach KA, Gonen M, Tang LH, et al. Downstaging in pancreatic cancer: a matched analysis of patients resected following treatment of initially locally unresectable disease. *Ann Surg Oncol* 2012;19:1663-1669.
4. Mondo EL, Noel MS, Katz W, ET AL. unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability. *J Clin Oncol* 2013;31:e37- 39.
5. Tempero MA, Berlin J, Ducreux M, et al pancreatic cancer treatment and research: an international expert panel discussion. *Ann Oncol* 2011;22:1500-1506.
6. Seiwert TY, Salama TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm—general principles. *Nat Clin Pract Oncol* 2007;4:86-100.
7. Girard N, Mornex F, Bossard N, et al estimating optimal dose of twice –weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 phase I trial. *Int J Radiat Oncol Biol Phys* 2010;77:1426-1432.
8. Murphy JD, Adusumilli S, Griffith KA, et al Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. *Int J Radiat Oncol Biol Phys* 2007;68:801-808
9. Ammori JB, Colletti LM, Zalupski MM, et al. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. *J Gastrointest Surg* 2003;7:766-772.
10. Marti JL, Hochster HS, Hiotis SP, et al. Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer. *Ann Surg Oncol* 2008;15:3521-3531.
11. Van Buren G, 2nd, Ramanathan RK, Krasinskas AM, et al. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. *Ann Surg Oncol* 2013;20:3787-3793

